|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TGFB3 |
Gene summary for TGFB3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TGFB3 | Gene ID | 7043 |
| Gene name | transforming growth factor beta 3 | |
| Gene Alias | ARVD | |
| Cytomap | 14q24.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | P10600 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 7043 | TGFB3 | ATC12 | Human | Thyroid | ATC | 1.21e-24 | 5.39e-01 | 0.34 |
| 7043 | TGFB3 | ATC13 | Human | Thyroid | ATC | 3.62e-26 | 4.99e-01 | 0.34 |
| 7043 | TGFB3 | ATC4 | Human | Thyroid | ATC | 5.43e-25 | 6.55e-01 | 0.34 |
| 7043 | TGFB3 | ATC5 | Human | Thyroid | ATC | 1.84e-32 | 5.46e-01 | 0.34 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:002241124 | Thyroid | ATC | cellular component disassembly | 248/6293 | 443/18723 | 1.34e-22 | 3.69e-20 | 248 |
| GO:1902903210 | Thyroid | ATC | regulation of supramolecular fiber organization | 210/6293 | 383/18723 | 6.20e-18 | 7.54e-16 | 210 |
| GO:007048228 | Thyroid | ATC | response to oxygen levels | 193/6293 | 347/18723 | 1.83e-17 | 1.93e-15 | 193 |
| GO:190495128 | Thyroid | ATC | positive regulation of establishment of protein localization | 177/6293 | 319/18723 | 5.43e-16 | 4.29e-14 | 177 |
| GO:003629328 | Thyroid | ATC | response to decreased oxygen levels | 177/6293 | 322/18723 | 1.81e-15 | 1.32e-13 | 177 |
| GO:0032970210 | Thyroid | ATC | regulation of actin filament-based process | 208/6293 | 397/18723 | 5.82e-15 | 3.80e-13 | 208 |
| GO:0007015210 | Thyroid | ATC | actin filament organization | 227/6293 | 442/18723 | 5.96e-15 | 3.85e-13 | 227 |
| GO:000166628 | Thyroid | ATC | response to hypoxia | 169/6293 | 307/18723 | 6.58e-15 | 4.12e-13 | 169 |
| GO:0032956210 | Thyroid | ATC | regulation of actin cytoskeleton organization | 190/6293 | 358/18723 | 1.73e-14 | 1.01e-12 | 190 |
| GO:005122234 | Thyroid | ATC | positive regulation of protein transport | 165/6293 | 303/18723 | 4.94e-14 | 2.69e-12 | 165 |
| GO:003134623 | Thyroid | ATC | positive regulation of cell projection organization | 186/6293 | 353/18723 | 7.99e-14 | 4.23e-12 | 186 |
| GO:007155925 | Thyroid | ATC | response to transforming growth factor beta | 142/6293 | 256/18723 | 4.30e-13 | 1.94e-11 | 142 |
| GO:000150332 | Thyroid | ATC | ossification | 206/6293 | 408/18723 | 9.23e-13 | 3.95e-11 | 206 |
| GO:0110053210 | Thyroid | ATC | regulation of actin filament organization | 150/6293 | 278/18723 | 1.82e-12 | 7.58e-11 | 150 |
| GO:004206034 | Thyroid | ATC | wound healing | 210/6293 | 422/18723 | 3.33e-12 | 1.37e-10 | 210 |
| GO:007156026 | Thyroid | ATC | cellular response to transforming growth factor beta stimulus | 137/6293 | 250/18723 | 3.69e-12 | 1.49e-10 | 137 |
| GO:0051495111 | Thyroid | ATC | positive regulation of cytoskeleton organization | 125/6293 | 226/18723 | 1.39e-11 | 5.08e-10 | 125 |
| GO:190290529 | Thyroid | ATC | positive regulation of supramolecular fiber organization | 117/6293 | 209/18723 | 2.19e-11 | 7.80e-10 | 117 |
| GO:000717924 | Thyroid | ATC | transforming growth factor beta receptor signaling pathway | 112/6293 | 198/18723 | 2.42e-11 | 8.44e-10 | 112 |
| GO:000170126 | Thyroid | ATC | in utero embryonic development | 183/6293 | 367/18723 | 6.62e-11 | 2.11e-09 | 183 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Breast | ADJ |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Breast | DCIS |
| TGFB3 | ACVR1_TGFbR | TGFB3_ACVR1_TGFBR1 | TGFb | Breast | DCIS |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Esophagus | ESCC |
| TGFB3 | ACVR1_TGFbR | TGFB3_ACVR1_TGFBR1 | TGFb | Esophagus | ESCC |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | HNSCC | OSCC |
| TGFB3 | ACVR1_TGFbR | TGFB3_ACVR1_TGFBR1 | TGFb | HNSCC | OSCC |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | HNSCC | Precancer |
| TGFB3 | ACVR1_TGFbR | TGFB3_ACVR1_TGFBR1 | TGFb | HNSCC | Precancer |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Lung | ADJ |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Lung | IAC |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Prostate | ADJ |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | Prostate | BPH |
| TGFB3 | TGFbR1_R2 | TGFB3_TGFBR1_TGFBR2 | TGFb | THCA | Cancer |
| TGFB3 | ACVR1B_TGFbR2 | TGFB3_ACVR1B_TGFBR2 | TGFb | THCA | Cancer |
| TGFB3 | ACVR1_TGFbR | TGFB3_ACVR1_TGFBR1 | TGFb | THCA | Cancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TGFB3 | SNV | Missense_Mutation | novel | c.147N>A | p.Ser49Arg | p.S49R | P10600 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-5T-A9QA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
| TGFB3 | SNV | Missense_Mutation | c.610G>A | p.Val204Ile | p.V204I | P10600 | protein_coding | tolerated(0.06) | possibly_damaging(0.615) | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| TGFB3 | insertion | Frame_Shift_Ins | novel | c.1193_1194insCCCTGTCCTAAAATCCTGGCTGGCG | p.Glu399ProfsTer20 | p.E399Pfs*20 | P10600 | protein_coding | TCGA-A2-A04V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | PD | ||
| TGFB3 | insertion | Frame_Shift_Ins | novel | c.135_136insGGGTGCCC | p.Gln46GlyfsTer6 | p.Q46Gfs*6 | P10600 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TGFB3 | insertion | In_Frame_Ins | novel | c.134_135insGCCTAGTGCTGGCCACACAGC | p.Gly45_Gln46insProSerAlaGlyHisThrAla | p.G45_Q46insPSAGHTA | P10600 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| TGFB3 | insertion | Nonsense_Mutation | novel | c.796_797insTCAGTTAGTTCCCTATGAAGG | p.Arg266delinsLeuSerTerPheProMetLysGly | p.R266delinsLS*FPMKG | P10600 | protein_coding | TCGA-BH-A0E2-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | ||
| TGFB3 | SNV | Missense_Mutation | novel | c.413C>T | p.Ser138Leu | p.S138L | P10600 | protein_coding | tolerated(0.12) | benign(0.152) | TCGA-C5-A1MP-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TGFB3 | SNV | Missense_Mutation | rs868258653 | c.463N>T | p.Arg155Trp | p.R155W | P10600 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| TGFB3 | SNV | Missense_Mutation | rs368004396 | c.580C>T | p.Arg194Trp | p.R194W | P10600 | protein_coding | deleterious(0) | probably_damaging(0.948) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| TGFB3 | SNV | Missense_Mutation | novel | c.284N>G | p.Asn95Ser | p.N95S | P10600 | protein_coding | tolerated(0.85) | benign(0.023) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 7043 | TGFB3 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | antibody | FRESOLIMUMAB | FRESOLIMUMAB | |
| 7043 | TGFB3 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | inhibitor | CHEMBL1743022 | FRESOLIMUMAB | |
| 7043 | TGFB3 | TRANSCRIPTION FACTOR, DRUGGABLE GENOME, CELL SURFACE, GROWTH FACTOR | Avotermin | AVOTERMIN |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |